• Jeffrey P. Callen


Mycophenolate Mofetil Inclusion Body Myositis Cutaneous Manifestation Idiopathic Inflammatory Myopathy Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abernethy ML, Arterberry JF, Callen JP (1996) Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Dermatology 192(2): 153–155PubMedGoogle Scholar
  2. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000a) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27: 2498–2503PubMedGoogle Scholar
  3. Al-Mayouf S, Al-Mazyed A, Bahabri S (2000b) Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19: 138–141CrossRefPubMedGoogle Scholar
  4. Airio A, Pukkala E, Isomäki (1995) Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol 22: 1300–1303PubMedGoogle Scholar
  5. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292: 344–347 and 403–407 (two part article)PubMedGoogle Scholar
  6. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56: 255–286PubMedGoogle Scholar
  7. Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high dose intravenous methylprednisolone (IV pulse) prevents calcinosis and shortens disease course in juvenile dermatomyositis (JDMS). Arth Rheum 37: R10AGoogle Scholar
  8. Callen JP (1982) The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 6: 253–259PubMedGoogle Scholar
  9. Callen JP (1993) Photodermatitis in a 6-year-old child. Arhthritis Rheum 36: 1483–1485Google Scholar
  10. Callen JP (1999) Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg 18(4): 293–296PubMedGoogle Scholar
  11. Callen JP (2000) Dermatomyositis. Lancet 355: 53–57PubMedGoogle Scholar
  12. Callen JP (2000) When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer? Arch Dermatol 138: 969–971Google Scholar
  13. Cheong W-K, Hughes GRV, Norris PG, Hawk JLM (1994) Cutaneous photosensitivity in dermatomyositis. Brit J Dermatol 131: 205–208Google Scholar
  14. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002): Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis. Arthritis Rheum 46: 467–74.CrossRefPubMedGoogle Scholar
  15. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark. Cancer Causes and Control 5: 9–13CrossRefGoogle Scholar
  16. Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, Roujeau JC (1995) Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 131: 1381–1385CrossRefPubMedGoogle Scholar
  17. Dacey MJ, Callen JP (2003) Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol 48: 439–441.CrossRefPubMedGoogle Scholar
  18. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000CrossRefPubMedGoogle Scholar
  19. Dalakas MC (1998) Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 54: 1509–1512CrossRefGoogle Scholar
  20. Daoud MS, Gibson LE, Pittelkow MR (1997) Hydroxyurea dermopathy. A unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 36: 178–182PubMedGoogle Scholar
  21. Douglas WW, Tazezlaer HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 164: 1182–5.PubMedGoogle Scholar
  22. Dourmishev AL, Dourshimev LA (1999) Dermatomyositis and drugs. Adv Exp Med Biol 445: 187–191Google Scholar
  23. E1-Azhary RA, Pakzad SY (2002) Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 46: 560–565CrossRefPubMedGoogle Scholar
  24. Euwer RL, Sontheimer RD (1991) Amyopathic DM (DM sine myositis). J Am Acad Dermatol 24: 959–966PubMedGoogle Scholar
  25. Garcia J (2000) MRI in inflammatory myopathies. Skeletal Radiol 29: 425–438Google Scholar
  26. Gelber AC, Nousari HC, Wigley FM (2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27: 1542–1545PubMedGoogle Scholar
  27. Ghali FE, Stein LD, Fine J-D, Burkes EJ, McCauliffe DP (1999) Gingival telangiectases. An underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol 135: 1370–1374CrossRefPubMedGoogle Scholar
  28. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, Rosas E, Suarez-Almazor M, Cardona-Munoz C, Ramos-Remus C (1996) Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 14: 373–379PubMedGoogle Scholar
  29. Hengstman G, van den Hoogen F, van Engelen B, Barrera P, Netea M, van den Putte L (2000) Anti-TNF-blockade with infliximab (remicade) in polymyositis and dermatomyositis. Arthritis Rheum 43: S193AGoogle Scholar
  30. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evan SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 357: 96–100CrossRefPubMedGoogle Scholar
  31. Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, Chanoine J-P, Petty RE (2001) Lipodystrophy in patients with juvenile dermatomyositis — evaluation of clinical and metabolic abnormalities. J Rheumatol 28: 610–615.PubMedGoogle Scholar
  32. Hollar CB, Jorizzo JL (2004) Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 15: 35–9.CrossRefPubMedGoogle Scholar
  33. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P (2000) Medium-and long-tern functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43: 541–549PubMedGoogle Scholar
  34. Kasteler JS, Callen JP (1994) Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 272: 1939–1941CrossRefPubMedGoogle Scholar
  35. Kasteler JS, Callen JP (1997) Low-dose methotrexate administered weekly in an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 36: 67–71PubMedGoogle Scholar
  36. Kaufmann R, Greiner D, Schmidt P, Wolter M (1998) Dermatomyositis presenting as plaque-like mucinosis. Brit J Dermatol 138: 889–892CrossRefGoogle Scholar
  37. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-a expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99: 585–588CrossRefPubMedGoogle Scholar
  38. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70(6): 360–374PubMedGoogle Scholar
  39. Lundberg IE, Nyberg P (1998) New developments in the role of cytokines and chemokines in inflammatory myopathies. Curr Opinion in Rheumatol 10: 521–529Google Scholar
  40. Marie I, Hatron P-Y, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B (1998) Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 25: 1336–1343PubMedGoogle Scholar
  41. Marie I, Hatron PY, Levesque H, Hachulla E, Hellot MF, Michon-Pasturel U, Courtois H, Devulder B (1999) Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine 78: 139–147CrossRefPubMedGoogle Scholar
  42. Marie I, Joly P, Levesque H, Heron F, Courville P, Cailleux N, Courtois H (2000) Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol 18: 536–537PubMedGoogle Scholar
  43. McCollough ML, Cockerell CJ (1998) Vesiculo-Bullous Dermatomyositis. Am J Dermatopathol 20: 170–174CrossRefPubMedGoogle Scholar
  44. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326: 1380–1384PubMedGoogle Scholar
  45. Nousari HC, Ha VT, Laman SD, Provost TT, Tausk FA (1999) ‘Centripetal Flagellate Erythema’: A Cutaneous Manifestation Associated with Dermatomyositis. J Rheumatol 26: 692–695PubMedGoogle Scholar
  46. Nyberg P, Wikman A-L, Nennesmo I, Lundberg I (2000) Increased expression of Interleukin 1a and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 27: 940–948PubMedGoogle Scholar
  47. Oliveri MB, Palermo R, Mautalen C, Hübscher O (1996) Regression of calcinosis during Diltiazem treatment of juvenile dermatomyositis. J Rheumatol 23: 2152–2155PubMedGoogle Scholar
  48. Pachman LM (1995) An update on juvenile dermatomyositis. Curr Opin Rheumatol 7: 437–441PubMedGoogle Scholar
  49. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH (2000) TNFa-308A allele in juvenile dermatomyositis. Arthritis Rheum 43: 2368–2377PubMedGoogle Scholar
  50. Pautas E, Cherin P, Piette J-C, Pelletier S, Wechsler B, Cabane J, Herson S (2000) Features of polymyositis and dermatomyositis in the elderly: A case-control study. Clin Exp Rheumatol 18: 241–244PubMedGoogle Scholar
  51. Pelle MT, Callen JP (2002) Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 138: 1231–1233CrossRefPubMedGoogle Scholar
  52. Peng J-C, Sheem T-S, Hsu M-M (1995) Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121: 1298–1301PubMedGoogle Scholar
  53. Plotz PH, Rider LG, Targoff IN, Raben N, O’Hanlon TP, Miller FW (1995) Myositis: Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy. Ann Intern Med 122: 715–724PubMedGoogle Scholar
  54. Requena L, Grilli R, Soriano L, Escalonilla P, Farina C, Martin L (1997) Dermatomyositis with a pityriasis rubra pilaris-like eruption: a little-known distinctive cutaneous manifestation of dermatomyositis. Brit J Dermatol 136: 768–771Google Scholar
  55. Rockerbie NR, Woo TY, Callen JP, Giustina T (1989) Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 20: 629–632PubMedGoogle Scholar
  56. Saadeh CK (2000) Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arhtritis Rheum 43: S193AGoogle Scholar
  57. Sawhney S, Sidoti G, Woo P, Murray KJ (2000) Clinical characteristics and outcome of idiopathic inflammatory myositis (IIM) in childhood: A 2 year follow up. Arthritis Rheum 43: AGoogle Scholar
  58. Sayers ME, Chou SM, Calabrese LH (1992) Inclusion body myositis: Analysis of 32 cases. J Rheumatol 19: 1385–1389PubMedGoogle Scholar
  59. Shannon PL, Ford MJ (1999) Angiokeratomas in juvenile dermatomyositis. Pediatr Dermatol 16: 448–451CrossRefPubMedGoogle Scholar
  60. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19: 352–359CrossRefPubMedGoogle Scholar
  61. Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46: 626–636.CrossRefPubMedGoogle Scholar
  62. Spiera R, Kagen L (1998) Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opinion in Rheumatol 10: 556–561Google Scholar
  63. Siguregeirsson B, Lindelöf B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 325: 363–367Google Scholar
  64. Sinoway PA, Callen JP (1993) Chlorambucil: An Effective Corticosteroid-Sparing Agent for Patients with Recalcitrant Dermatomyositis. Arthritis Rheum 36: 319–324PubMedGoogle Scholar
  65. Sugugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M, Kamatani N (2000) Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: Role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-5, and monocyte chemoattractant protein-1 production. J Immunol 164: 6593–6000PubMedGoogle Scholar
  66. Stonecipher MR, Jorizzo JL, White WL, Walker FO, Prichard E (1993) Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: DM sine myositis? J Am Acad Dermatol 28: 951–956PubMedGoogle Scholar
  67. Targoff IN (1991) Dermatomyositis and polymyositis. Curr Prob Dermatol 3: 131–180CrossRefGoogle Scholar
  68. Targoff IN, Trieu EP, Sontheimer RD (2000) Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis. Arthritis Rheum 43: S194AGoogle Scholar
  69. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafvova J, Bartunkova J, Nemcova D, Charvat F (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29: 95–102CrossRefPubMedGoogle Scholar
  70. Villalba L, Adams EM (1996) Update on therapy for refractory dermatomyositis and polymyositis. Curr Opinion Rheumatol 8: 544–551Google Scholar
  71. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW (1998) Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41(3): 392–399PubMedGoogle Scholar
  72. Wanchu A, Khullar M, Sud A, Bambery P (1999) Nitric oxide production is increased in patient with inflammatory myositis. Nitric Oxide 3: 454–458CrossRefPubMedGoogle Scholar
  73. Whitmore SE, Rosenshein NB, Provost TT (1994) Ovarian cancer in patients with dermatomyositis. Medicine 73: 153–160PubMedGoogle Scholar
  74. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10: 592–600PubMedGoogle Scholar
  75. Woo TR, Rasmussen J, Callen JP (1985) Recurrent photosensitive dermatitis preceding juvenile dermatomyositis. Pediatr Dermatol 2: 207–212PubMedGoogle Scholar
  76. Wortmann RL (2001) Idiopathic Inflammatory diseases of muscle. In Treatment of the Rheumatic Diseases. Weisman ML, Weinblatt ME, Louie JS (eds) W. B. Saunders Co. pp 390–402Google Scholar
  77. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD (1995) Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 32: 754–757CrossRefPubMedGoogle Scholar
  78. Zuber M, John S, Pfreundschuh M, Gause A (1996) A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum 39: 1419–1422PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2005

Authors and Affiliations

  • Jeffrey P. Callen

There are no affiliations available

Personalised recommendations